全文获取类型
收费全文 | 48605篇 |
免费 | 3326篇 |
国内免费 | 2313篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 1099篇 |
妇产科学 | 665篇 |
基础医学 | 4949篇 |
口腔科学 | 930篇 |
临床医学 | 5531篇 |
内科学 | 8252篇 |
皮肤病学 | 1551篇 |
神经病学 | 1622篇 |
特种医学 | 1350篇 |
外国民族医学 | 8篇 |
外科学 | 3611篇 |
综合类 | 7129篇 |
现状与发展 | 5篇 |
一般理论 | 1篇 |
预防医学 | 2997篇 |
眼科学 | 546篇 |
药学 | 9250篇 |
80篇 | |
中国医学 | 1690篇 |
肿瘤学 | 2724篇 |
出版年
2024年 | 69篇 |
2023年 | 945篇 |
2022年 | 1324篇 |
2021年 | 2120篇 |
2020年 | 2009篇 |
2019年 | 1633篇 |
2018年 | 1505篇 |
2017年 | 1440篇 |
2016年 | 1446篇 |
2015年 | 1504篇 |
2014年 | 3009篇 |
2013年 | 3015篇 |
2012年 | 2747篇 |
2011年 | 3097篇 |
2010年 | 2638篇 |
2009年 | 2273篇 |
2008年 | 2403篇 |
2007年 | 2556篇 |
2006年 | 2128篇 |
2005年 | 2075篇 |
2004年 | 1641篇 |
2003年 | 1574篇 |
2002年 | 1299篇 |
2001年 | 1206篇 |
2000年 | 1071篇 |
1999年 | 987篇 |
1998年 | 892篇 |
1997年 | 822篇 |
1996年 | 605篇 |
1995年 | 675篇 |
1994年 | 595篇 |
1993年 | 441篇 |
1992年 | 422篇 |
1991年 | 323篇 |
1990年 | 245篇 |
1989年 | 177篇 |
1988年 | 154篇 |
1987年 | 146篇 |
1986年 | 130篇 |
1985年 | 131篇 |
1984年 | 130篇 |
1983年 | 98篇 |
1982年 | 117篇 |
1981年 | 96篇 |
1980年 | 67篇 |
1979年 | 58篇 |
1978年 | 43篇 |
1977年 | 59篇 |
1976年 | 44篇 |
1973年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 484 毫秒
1.
Defining con-founders that affect the reliability of diagnostic tests for coronavirus disease 2019 is vital to breaking the chain of infection. The elderly population is a higher risk group for the emerging virus. However, gender seems to exert a critical role in modifying the infection risk among women owing to hormonal changes. The menopause transition is an exceptional period for older women where the protective and immunomodulatory effects of the estrogen hormone are lost. Accordingly, attention should be given to postmenopausal women since they will have an increased risk compared to their pre-menopausal peers. 相似文献
2.
3.
《Clinical microbiology and infection》2022,28(8):1120-1125
ObjectivesOur aim was to evaluate the effect of the updated European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group 2019 definitions for invasive pulmonary aspergillosis (IPA) on patient classification and the related all-cause 12-week mortality.MethodsIn this retrospective cohort study from our tertiary care centre, we reclassified patients with haematological malignancy who underwent bronchoalveolar lavage between 2014 and 2019 for suspected IPA using the novel EORTC 2019 criteria. We performed receiver operating characteristic curve analysis to define the optimal cut-off for positive PCR and galactomannan and present survival analyses and their possible association with these diagnostic criteria through post hoc comparisons with log rank and Cox regression.ResultsFrom 323 episodes of suspected IPA in 282 patients, 73 were reclassified: 31 (42.5%) from possible to probable IPA, 5 (6.8%) from EORTC criteria not met to probable IPA, and 37 (50.7%) from EORTC criteria not met to possible IPA. Probable IPA increased therefore 11.1% (64/323, 19.8% to 100/323, 30.9%), mostly due to positive PCR (31/36, 86.1%). There was no difference in mortality between newly defined possible and probable IPA (log rank p = 0.950). Mortality was higher in probable cases with lower cycle thresholds (Ct values) versus higher Ct values (p = 0.004). Receiver operating characteristic curve analysis showed an optimal Ct value cut-off of 36.8 with a sensitivity of 75% (95% CI 64.9%–85.1%) and a specificity of 61.7% (95% CI 53.5–69.9) for 12-week mortality.DiscussionThe new EORTC criteria led to 11.1% more probable IPA diagnoses, mostly due to Aspergillus PCR. Restricting positive PCR to below a certain threshold might improve the discrimination of the new EORTC IPA categories for mortality. 相似文献
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
5.
《Digestive and liver disease》2022,54(11):1486-1493
BackgroundCold snare polypectomy (CSP) is a promising technique for the removal of sessile serrated polyps (SSPs) ≥ 10 mm. However, the efficacy and safety of this technique remain undetermined.AimsWe aimed to comprehensively evaluate the efficacy and safety of CSP for SSPs ≥ 10 mm.MethodsPubMed, EMBASE, Web of Science and Cochrane Library were searched up to January 2021.ResultsA total of 10 studies consisting of 1727 SSPs (range, 10–40 mm) from 1021 patients were included. The overall rates of technical success, adverse events (AEs) and residual SSPs were 100%, 0.7% and 2.9%, respectively. Subgroup analysis showed that the rates of technical success and AEs were comparable between CSP and cold endoscopic mucosal resection (EMR) (99.9% vs. 100% and 1.3% vs. 0.5%, respectively), between the proximal and distal colon (100% vs. 99.9% and 0.3% vs. 0, respectively), and between polyps of 10–19 mm and ≥20 mm (99.8% vs. 100% and 0.9% vs. 0, respectively). However, subgroup analysis showed that the rate of residual SSPs was slightly lower in CSP compared with cold EMR (1.3% vs. 3.9%), as well as in polyps of 10–19 mm compared with those ≥20 mm (3.1% vs. 4.7%).ConclusionCSP was an effective and safe technique for removing SSPs ≥ 10 mm. 相似文献
6.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
8.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
9.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
10.
目的:探讨阿帕替尼单药在标准治疗方案失败晚期结直肠癌(colorectal cancer,CRC)患者中的疗效和安全性。方法:本研究为前瞻性研究设计,用PASS15 软件计算研究所需的样本量,从2017 年7 月到2018 年8 月入组标准方案治疗失败的晚期CRC患者52 例,给予阿帕替尼起始剂量750 mg或500 mg单药治疗;评估患者的客观缓解率(ORR)和疾病控制率(DCR),随访评价患者的无进展生存期(PFS)和总生存期(OS),并记录治疗过程中出现的不良反应。主要研究终点为PFS,次要研究终点为ORR、DCR、OS和安全性。结果:纳入研究的52 例CRC患者中45 例可以评价疗效及安全性,其均为既往接受过至少2 次系统性化疗的晚期CRC患者。疗效:完全缓解0 例、部分缓解5 例、疾病稳定30 例、疾病进展10 例,ORR为11.11%、DCR为77.78%;预后:45 例患者的中位PFS 为3.95 个月(95% CI=3.16~4.74),中位OS为10.3 个月(95% CI=5.70~14.90);3 级以上不良反应:手足综合征6 例(13.33%),高血压5 例(11.11%),蛋白尿5 例(6.67%),转氨酶升高4 例(8.89%),腹泻3 例(6.67%),疲劳2 例(4.44%),出血1例(2.22%)。结论:阿帕替尼单药治疗标准方案失败的晚期CRC患者具有潜在的临床获益,安全性事件总体可控。 相似文献